Accepted for Publication: January 12, 2011.
Published Online: March 14, 2011. doi:10.1001/archneurol.2011.34
Author Contributions:Study concept and design: Magaña, Keegan, Weinshenker, Erickson, Rodriguez, and Lucchinetti. Acquisition of data: Magaña, Keegan, Weinshenker, Erickson, Pittock, Lennon, Rodriguez, Linbo, and Lucchinetti. Analysis and interpretation of data: Magaña, Keegan, Weinshenker, Erickson, Pittock, Rodriguez, Thomsen, Weigand, Mandrekar, and Lucchinetti. Drafting of the manuscript: Magaña and Lucchinetti. Critical revision of the manuscript for important intellectual content: Magaña, Keegan, Weinshenker, Erickson, Pittock, Lennon, Rodriguez, Thomsen, Weigand, Mandrekar, Linbo, and Lucchinetti. Statistical analysis: Magaña, Thomsen, Weigand, Mandrekar, and Lucchinetti. Obtained funding: Pittock and Lucchinetti. Administrative, technical, and material support: Magaña, Erickson, and Rodriguez. Study supervision: Magaña, Keegan, and Lucchinetti.
Financial Disclosure: Drs Lennon, Lucchinetti, and Weinshenker stand to receive royalties for intellectual property related to the aquaporin 4 autoantigen. Dr Keegan is compensated as section editor for Neurology and as a chief editor for eMedicine. Dr Pittock and Mayo Clinic have a financial interest in the technology entitled “Aquaporin-4 Autoantibody as a Cancer Marker.” This technology has been licensed to a commercial entity but no royalties have been received. Dr Pittock is an inventor of technology entitled “Aquaporin-4 Binding Autoantibodies in Patients With Neuromyelitis Optica Impair Glutamate Transport by Down-Regulating EAAT2.” Mayo Clinic has filed a nonprovisional patent application for this technology. Dr Pittock has received a research grant from Alexion Pharmaceuticals for his investigator-initiated study entitled “An Open Label Study of Eculizumab in NMO.” Dr Pittock is a consultant in the Department of Laboratory Medicine and Pathology. In his role as codirector of the Neuroimmunology Laboratory, Dr Pittock has no additional intellectual property related to any tests performed on a service basis in the laboratory. Dr Pittock receives no royalties from the sale of these tests when used for patients. Mayo Collaborative Services, Inc, does receive revenue for conducting these tests.
Funding/Support: This work was funded by Mayo Foundation, Clinical Translational Science grant 1 TL1 RR024152-01 from the National Institutes of Health (Ms Magaña), grant RG-3185-B-3 from the National MS Society (Dr Lucchinetti), grant NS-49577-01 from the National Institute of Neurological Disorders and Stroke (Dr Lucchinetti), and a generous gift from the Guthy-Jackson Charitable Foundation.
Role of the Sponsors: The sponsors had no role in the study design, data collection, data analysis, data interpretation, or writing of the manuscript and were not involved in the decision to submit the manuscript for publication.
Additional Contributions: Jeffrey Winters, MD, and the Mayo Clinic Apheresis Unit assisted in patient ascertainment and Lea Dacy, AB, assisted with manuscript preparation.